Prevalence of storage and voiding symptoms among men aged 40 years and older in a US population-based study: results from the Male Attitudes Regarding Sexual Health study

Authors


  • Disclosures
    Dale B. Glasser is employed by Pfizer Inc. Culley Carson serves as a speaker, advisory board member and the study investigator for GlaxoSmithKline, Lilly and Pfizer Inc. Jeong-han Kang worked as a Statistical Research Assistant for Dr Laumann, who received a grant from Pfizer Inc. to support the statistical analyses. Dr Laumann has been on the scientific advisory committee for MARSH for more than 5 years (taking the lead in directing the data analysis and write-up). He has no stockholdings in Pfizer and has no other working relationship with Pfizer, but he recently began working as a scientific consultant for Boehringer Ingelheim Pharmaceuticals, Inc.


Dale B. Glasser, PhD,
235 East 42nd Street, MS 685/19/7, New York, NY 10017, USA
Tel.: + 1 212 573 5951
Fax: + 1 212 973 7130
Email: dale.glasser@pfizer.com

Summary

Aims:  Lower urinary tract symptoms (LUTS) are categorised as storage (urgency, frequency, nocturia and incontinence), voiding (sensation of incomplete emptying, hesitancy, weak stream and straining) or mixed symptoms.

Methods:  In this US population-based study, we investigated the prevalence of male LUTS and the relative frequency of the LUTS subtypes, and we evaluated associations between LUTS and age, race/ethnicity and erectile dysfunction (ED). The Male Attitudes Regarding Sexual Health study included a nationally representative sample of non-Hispanic black, non-Hispanic white and Hispanic men aged ≥ 40 years. Participants completed a questionnaire including items on ED and the International Prostate Symptom Score (IPSS). The prevalence and subtypes of LUTS were investigated post hoc by age, race/ethnicity and the presence of ED.

Results:  The overall prevalence rates of storage (13%) and mixed (9%) symptoms were higher than that of voiding symptoms (6%). The prevalence of storage symptoms was similar across age groups, whereas voiding and mixed symptoms increased with age. Among men with IPSS ≥ 8, the rates of storage (29%) and mixed (38%) symptoms were also higher than voiding symptoms (23%). Distributions of the LUTS subtypes were comparable among black, white and Hispanic respondents with IPSS ≥ 8. The overall prevalence rate of ED (40%) increased with age among those with IPSS ≥ 8. Isolated storage symptoms were more than twice as common as isolated voiding symptoms among US men ≥ 40 years of age.

Conclusion:  Careful attention to individual symptoms may help distinguish storage LUTS from voiding LUTS, a distinction that has important implications for treatment.

Ancillary